Global Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Forecast 2024-2030- Product Image

Sale

Global Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Forecast 2024-2030

Report
181 Pages
March 2024
Region: Global
360iResearch™
ID: 5888909

UP TO €846EUR$875USD£725GBP OFF until Dec 31^st 2024

The Lysosomal Storage Diseases Market size was estimated at USD 9.31 billion in 2023, USD 9.98 billion in 2024, and is expected to grow at a CAGR of 7.48% to reach USD 15.43 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lysosomal Storage Diseases Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lysosomal Storage Diseases Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, ArmaGen, Inc., BioMarin, CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Lysogene, Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix, Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc.

Market Segmentation & Coverage

This research report categorizes the Lysosomal Storage Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease Type
- Fabry Diseases
- Gaucher's Diseases
- Mucopolysaccharidosis
- Pompe's Syndrome
Type of Therapy
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
End User
- Clinics
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Lysosomal Storage Diseases Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lysosomal Storage Diseases Market?
What are the technology trends and regulatory frameworks in the Lysosomal Storage Diseases Market?
What is the market share of the leading vendors in the Lysosomal Storage Diseases Market?
Which modes and strategic moves are suitable for entering the Lysosomal Storage Diseases Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Lysosomal Storage Diseases Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of lysosomal storage disorders worldwide
5.1.1.2. Inclination toward early diagnosis and treatment of diseases
5.1.1.3. Increasing use of enzyme replacement therapies
5.1.2. Restraints
5.1.2.1. High cost associated with the treatment of t lysosomal storage disease
5.1.3. Opportunities
5.1.3.1. Advancements in gene editing technologies and gene therapies
5.1.3.2. Emergence of personalized medicine approach to treat lysosomal storage conditions
5.1.4. Challenges
5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Lysosomal Storage Diseases Market, by Disease Type

6.1. Introduction
6.2. Fabry Diseases
6.3. Gaucher's Diseases
6.4. Mucopolysaccharidosis
6.5. Pompe's Syndrome

7. Lysosomal Storage Diseases Market, by Type of Therapy

7.1. Introduction
7.2. Enzyme Replacement Therapy
7.3. Stem Cell Therapy
7.4. Substrate Reduction Therapy

8. Lysosomal Storage Diseases Market, by End User

8.1. Introduction
8.2. Clinics
8.3. Hospitals

9. Americas Lysosomal Storage Diseases Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Lysosomal Storage Diseases Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Lysosomal Storage Diseases Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Abeona Therapeutics Inc.
13.1.2. Alexion Pharmaceuticals, Inc.
13.1.3. Amicus Therapeutics
13.1.4. ArmaGen, Inc.
13.1.5. BioMarin
13.1.6. CHIESI USA, Inc.
13.1.7. Denali Therapeutics Inc.
13.1.8. Freeline Therapeutics
13.1.9. Homology Medicines, Inc.
13.1.10. Horizon Pharma PLC
13.1.11. Idorsia Pharmaceuticals Ltd.
13.1.12. JCR Pharmaceuticals Co., Ltd.
13.1.13. Lysogene
13.1.14. Neurogene Inc.
13.1.15. Novartis AG
13.1.16. Orchard Therapeutics Limited
13.1.17. Pfizer Inc.
13.1.18. Protalix
13.1.19. Sangamo Therapeutics, Inc.
13.1.20. Sanofi S.A.
13.1.21. Spark Therapeutics, Inc.
13.1.22. Swedish Orphan Biovitrum AB
13.1.23. Takeda Pharmaceutical Company Limited
13.1.24. Ultragenyx Pharmaceutical Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2023 VS 2030
FIGURE 3. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
FIGURE 7. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
FIGURE 10. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 12. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 6. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER'S DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 11. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 15. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 28. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 29. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 32. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 45. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 46. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 48. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 49. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 55. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 73. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 86. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 89. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 92. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 95. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 100. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 101. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 110. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 112. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 113. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 115. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 116. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 128. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 137. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. LYSOSOMAL STORAGE DISEASES MARKET LICENSE & PRICING

Companies Mentioned

Abeona Therapeutics Inc.
Alexion Pharmaceuticals, Inc.
Amicus Therapeutics
ArmaGen, Inc.
BioMarin
CHIESI USA, Inc.
Denali Therapeutics Inc.
Freeline Therapeutics
Homology Medicines, Inc.
Horizon Pharma PLC
Idorsia Pharmaceuticals Ltd.
JCR Pharmaceuticals Co., Ltd.
Lysogene
Neurogene Inc.
Novartis AG
Orchard Therapeutics Limited
Pfizer Inc.
Protalix
Sangamo Therapeutics, Inc.
Sanofi S.A.
Spark Therapeutics, Inc.
Swedish Orphan Biovitrum AB
Takeda Pharmaceutical Company Limited
Ultragenyx Pharmaceutical Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	181
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 9.98 Billion
Forecasted Market Value ( USD ) by 2030	$ 15.43 Billion
Compound Annual Growth Rate	7.4%
Regions Covered	Global
No. of Companies Mentioned	24

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,796GBP €3625EUR$3,749USD£3,107GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,542GBP €4593EUR$4,749USD£3,936GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,288GBP €5560EUR$5,749USD£4,765GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£5,034GBP €6527EUR$6,749USD£5,594GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,526GBP €8461EUR$8,749USD£7,251GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Lysosomal Storage Diseases - Global Strategic Business Report

Lysosomal Storage Diseases Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

Lysosomal Storage Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Lysosomal Disease Treatment Global Market Report 2024

Lysosomal Storage Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028